Company intelligence / Profile preview

GeneCast Biotechnology

Beijing, Beijing, Chinaenglish.genecast.com.cn ↗

Ownership: Private
Development stage: Commercial

Overview

GeneCast has launched several commercial molecular diagnostic products for oncology. These include the ADPS™ EGFR Mutation Test Kit v1 and licensed MammaPrint/BluePrint tests for breast cancer risk stratification. The company is recognized as a leader in precision oncology diagnostics in China and South Korea with international certifications and partnerships

Therapeutic areas: Oncology
Modalities: Molecular diagnostics (liquid biopsy, NGS-based tests)Companion diagnostics
Industry: Molecular Diagnostics

Drug pipeline

1 asset

THEMIS

Commercial

Indications: Cancer detection

Partnerships

Agendia Inc. – exclusive partner to launch MammaPrint and BluePrint genomic tests in China

Beyond the preview

Go deeper on GeneCast Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GeneCast Biotechnology.

Explore the full profile